Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 36, Issue 7, 2017, Pages 1305-1315

  Souli, M ^a   Karaiskos, I ^b   Masgala, A ^b   Galani, L ^b   Barmpouti, E ^b   Giamarellou, H ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE KPC-2, KLEBSIELLA PNEUMONIAE; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DRUG MEGADOSE; FEMALE; GREECE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SEPSIS; SEPTIC SHOCK; URINARY TRACT INFECTION; VERY ELDERLY; COMPLICATION; ENZYMOLOGY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIOLOGY; PROCEDURES; SECRETION (PROCESS); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; CATHETER-RELATED INFECTIONS; FEMALE; GREECE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; THIENAMYCINS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 85013082492     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-017-2936-5     Document Type: Article

References (33)

1. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD et al (2001) Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161
2. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL (2014) Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862–872
3. Karaiskos I, Giamarellou H (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15:1351–1370
4. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A et al (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328
5. Bulik CC, Nicolau DP (2011) Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55:3002–3004
6. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332
7. Stevens V, Lodise TP, Tsuji B, Stringham M, Butterfield J, Dodds Ashley E et al (2012) The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 33:558–564
8. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(Suppl 11):1245–1251
9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
10. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
11. Clinical and Laboratory Standards Institute (2012) Performance Standards for Antimicrobial Susceptibility Testing: Twenty Second Informational Supplement M100-S22. CLSI, Wayne, PA, USA
12. European Committee on Antimicrobial Susceptibility Testing (2012) Breakpoint tables for interpretation of MICs and zone diameters, Version 2.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf
13. Tsakris A, Poulou A, Themeli-Digalaki K, Voulgari E, Pittaras T, Sofianou D et al (2009) Use of boronic acid disk tests to detect extended-spectrum beta-lactamases in clinical isolates of KPC carbapenemase-possessing enterobacteriaceae. J Clin Microbiol 47:3420–3426
14. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T et al (2010) An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 50:364–373
15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281
16. Thomson KS (2012) Double-carbapenem therapy not proven to be more active than carbapenem monotherapy against KPC-positive Klebsiella pneumoniae. Antimicrob Agents Chemother 56:4037
17. Oliva A, Gizzi F, Mascellino MT, Cipolla A, D’Abramo A, D’Agostino C et al (2016) Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol Infect 22:147–153
18. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S et al (2013) Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 57:2900–2901
19. Oliva A, D’Abramo A, D’Agostino C, Iannetta M, Mascellino MT, Gallinelli C et al (2014) Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream Infections. J Antimicrob Chemother 69:1718–1720
20. Poirel L, Kieffer N, Nordmann P (2016) In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 71:156–161
21. Wiskirchen DE, Crandon JL, Nicolau DP (2013) Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 41:582–585
22. Giamarellou H, Galani L, Baziaka F, Karaiskos I (2013) Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 57:2388–2390
23. Nogid B, Venugopalan V, Bias T, Rahman, D. Nicolau. Double carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae: from test tube to clinical practice. In: Abstracts of the twenty-third European Congress of Clinical Microbiology and Infectious Diseases, 2013. Abstract 2110. European Society of Clinical Microbiology and Infectious Diseases
24. Chua NG, Zhou YP, Tan TT, Lingegowda PB, Lee W, Lim TP et al (2015) Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. J Infect 70:309–311
25. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M et al (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133–2143
26. Oliva A, Mascellino MT, Cipolla A, D’Abramo A, De Rosa A, Savinelli S et al (2015) Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis 33:132–134
27. Camargo JF, Simkins J, Beduschi T, Tekin A, Aragon L, Pérez-Cardona A et al (2015) Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 59:5903–5908
28. Cprek JB, Gallagher JC (2016) Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 60:669–673
29. Oliva A, Cipolla A, Gizzi F, D’Abramo A, Favaro M, De Angelis M et al (2016) Severe bloodstream infection due to KPC-producer E coli in a renal transplant recipient treated with the double-carbapenem regimen and analysis of in vitro synergy testing: A case report. Medicine 95:e2243
30. Oliva A, Scorzolini L, Castaldi D, Gizzi F, De Angelis M, Storto M et al (2017) Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect 74:103–106
31. Karaiskos I, Souli M, Galani I, Giamarellou H (2017) Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol 13:59–71
32. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M et al (2015) Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study. Clin Microbiol Infect 21:1106.e1–1106.e8
33. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596